{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:34:11Z","timestamp":1792316051493,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00277-012-1422-5","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T02:16:55Z","timestamp":1329185815000},"page":"1013-1022","source":"Crossref","is-referenced-by-count":29,"title":["Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin\u2019s lymphoma patients"],"prefix":"10.1007","volume":"91","author":[{"given":"Luigi","family":"Rigacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Cortelazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Piccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"D\u2019Arco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Freilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Orciuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia","family":"Bongarzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Balzarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Rota-Scalabrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carpaneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Iannitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"1422_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin."},{"key":"1422_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/annonc\/mdi098","volume":"16","author":"P Boyle","year":"2005","unstructured":"Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481\u2013488","journal-title":"Ann. Oncol."},{"issue":"2","key":"1422_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/modpathol.3880035","volume":"13","author":"NL Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelik HK, Vardiman J, Lister TA, Bloomfield CD (2000) The Word Health Organization Classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Mod Pathol 13(2):193\u2013207","journal-title":"Mod Pathol."},{"issue":"8","key":"1422_CR4","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","volume":"80","author":"JM Vose","year":"1992","unstructured":"Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Prappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142\u20132148","journal-title":"Blood"},{"issue":"3","key":"1422_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3816\/CLML.2010.n.030","volume":"10","author":"RL Elstrom","year":"2010","unstructured":"Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP (2010) Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk 10(3):192\u2013196","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1422_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2165\/00003495-200161050-00009","volume":"61","author":"JA Barman Balfour","year":"2001","unstructured":"Barman Balfour JA, Goa KL (2001) Bendamustine. Drugs 61(5):631\u2013638","journal-title":"Drugs"},{"key":"1422_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliot G, Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkilating agents. Clin Cancer Res 14:309\u2013317","journal-title":"Clin Cancer Res"},{"key":"1422_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D, Harsdtrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistent human breast carcinoma cell lines. Anticancer Drugs 7:415\u2013421","journal-title":"Anticancer Drugs"},{"key":"1422_CR9","first-page":"640a","volume":"102","author":"LM Leoni","year":"2003","unstructured":"Leoni LM, Bailey B, Reifert J (2003) SDX-105 (bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood; 102:640a","journal-title":"Blood;"},{"issue":"2","key":"1422_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1586\/ehm.10.7","volume":"3","author":"M Montillo","year":"2010","unstructured":"Montillo M, Ricci F, Tedeschi A, Vismara E, Morra E (2010) Bendamustine: new perspective for an old drug in lymphoprolipherative disorders. Expert Rev Hematol 3(2):131\u2013148","journal-title":"Expert. Rev. Hematol."},{"key":"1422_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204\u2013210","journal-title":"J. Clin. Oncol."},{"key":"1422_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","volume":"128","author":"K Bremer","year":"2002","unstructured":"Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 128:603\u2013609","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1422_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/fon.10.169","volume":"7","author":"C Ujjani","year":"2011","unstructured":"Ujjani C, Cheson B (2011) Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. Future Oncol 7(1):9\u201314","journal-title":"Future Oncol"},{"key":"1422_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244\u20131253","journal-title":"J Clin Oncol."},{"key":"1422_CR15","unstructured":"SPSS Inc. (1998) SPSS for Windows, version 12.0. Chicago: SPSS."},{"key":"1422_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","volume":"12","author":"A Heider","year":"2001","unstructured":"Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphoma. Anticancer Drugs 12:725\u2013729","journal-title":"Anticancer Drugs"},{"key":"1422_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s004320000180","volume":"127","author":"R Kath","year":"2001","unstructured":"Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Research Clin Oncol 127:48\u201354","journal-title":"J. Cancer Research Clin Oncol."},{"key":"1422_CR18","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP.(2011) The combination of bendamustine,bortezomib and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, Jan 14 Epub","DOI":"10.1182\/blood-2010-11-314708"},{"issue":"15","key":"1422_CR19","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welsalu M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Holzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(15):3383\u20133389","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"1422_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3816\/CLML.2010.n.079","volume":"10","author":"BD Cheson","year":"2010","unstructured":"Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L (2010) Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(6):452\u2013457","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"1422_CR21","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","volume":"101","author":"K Ohmachi","year":"2010","unstructured":"Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059\u20132064","journal-title":"Cancer Sci"},{"key":"1422_CR22","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1080\/10428190400004521","volume":"45","author":"R Weide","year":"2004","unstructured":"Weide R, Pandorf A, Heymanns J et al (2004) Bendamustine\/mitoxantrone\/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20 positive indolent malignancies. Final results of a pilot study Leukemia and Lymphoma 45:2445\u20132449","journal-title":"Final results of a pilot study. Leukemia and Lymphoma"},{"key":"1422_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","volume":"132","author":"T Lissitchkov","year":"2006","unstructured":"Lissitchkov T, Arnaudov G, Peytchev D, Merkle KH (2006) Phase I\/II study to evaluate dose limiting toxicity, massimum tolerated doses, and tolerability of bendamustine HCL in pre-treated patients with B-chronic lymphocytic leukemia (binet stage) requiring therapy. J Cancer Res Clin Oncol 132:99\u2013104","journal-title":"J Cancer Res Clin Oncol"},{"key":"1422_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1023\/A:1008309911008","volume":"11","author":"P Schoffski","year":"2000","unstructured":"Schoffski P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, Kowalski R, Ganser A (2000) Weekly administration of bendamustine a phase I study in patients with advanced progressive solid tumors. Ann Oncol 11:729\u2013735","journal-title":"Ann Oncol"},{"key":"1422_CR25","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/sj.bjc.6603776","volume":"96","author":"M Rasschaert","year":"2007","unstructured":"Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB (2007) A phase I study of bendamustine hydrochloride administered day 1\u2009+\u20092 every 3 weeks in patients with solid tumors. Br J Cancer 96:1692\u20131698","journal-title":"Br J Cancer"},{"key":"1422_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3816\/CLML.2010.n.002","volume":"10","author":"BD Cheson","year":"2010","unstructured":"Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21\u201327","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1422_CR27","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balser C, Kaiser U, Ballo H, Weidmann E, Duerk HA, Kofahl-Krause D, Roller F, Barth J, Hoelzer D, Hinke A and Brugger W. (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Abs. 405 :51st ASH Meeting","DOI":"10.1182\/blood.V114.22.405.405"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1422-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1422-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T07:13:26Z","timestamp":1589958806000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1422-5"}},"subtitle":["A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)"],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1422"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1422-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}